IGIrene Girotto

Irene Girotto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Irene Girotto has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Matrix Matters: Head‐To‐Head Concordance of Serum and Plasma for NULISAseq CNS Disease Panel

    by Tommaso Merati, Chiara Tolassi, Alessandro Rondina, Irene Girotto, Marianna Bertoni, Eileen Mac Sweeney, Andrea Toja, Eqrem Rusi, Caterina Martinuzzo, Andrea Pilotto, et al.

    Blood‐based proteomic profiling is now widely applied in neurodegenerative and neuroinflammatory disease, yet the choice between serum and plasma remains poorly characterised for high‐multiplex platforms. Many biobanks consist predominantly of serum, whereas most current NUcleic‐acid‐Linked Immuno‐Sandwich Assay (NULISA) studies use plasma. We compared the 130‐protein NULISAseq central nervous system (CNS) Disease Panel head‐to‐head in matched serum and plasma collected at the same venipuncture from 62 participants (30 neurodegenerative, 19 demyelinating, 13 healthy controls). Agreement was measured with Spearman correlation (rho), Lin's concordance correlation coefficient (CCC), the intraclass correlation coefficient (ICC) and the mean paired plasma‐minus‐serum difference (dNPQ). Concordance was moderate to high: 114 of 130 proteins reached FDR significance and 18 reached rho ≥ 0.90, with a median rho of 0.65 (range 0.010–0.988). Proteins were classified into three concordance tiers (31, 6 and 30 proteins), with the remaining 63 showing intermediate concordance. Cytoskeletal markers (NEFH rho = 0.988; NEFL rho = 0.947) and glial GFAP (rho = 0.949, |dNPQ| < 0.5) were interchangeable between matrices. Phosphorylated tau (pTau) species retained excellent rank concordance but showed a systematic plasma‐greater‐than‐serum offset (pTau‐181 rho = 0.869, dNPQ = +0.67; pTau‐217 rho = 0.846, dNPQ = +0.64; pTau‐231 rho = 0.885, dNPQ = +0.89). Platelet‐derived analytes (CD40LG rho = 0.102, dNPQ = −4.74; BDNF rho = 0.223, dNPQ = −2.69) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) diverged markedly. For most clinically relevant neurodegeneration markers, especially cytoskeletal and glial proteins, serum is a valid substitute for plasma; absolute thresholds for phosphorylated tau require matrix‐specific calibration, whereas amyloid peptides and platelet‐sensitive analytes cannot be reliably compared across matrices without strictly standardised pre‐analytical conditions. image

  • Open Access

    Integrated NULISA-based CSF neuroimmune profiling reveals microglial–axonal injury signatures associated with early disability and NAWM damage in new-onset Multiple Sclerosis patients

    by Viviana Cristillo, Tommaso Merati, Chiara Tolassi, Alessandro Rondina, Valentina Bettonagli, Alice Galli, Irene Volonghi, Marta Bianchi, Davide Arici, Chiara Trasciatti, et al.

    BackgroundMultiple sclerosis (MS) is characterized by inflammatory demyelination, neuroaxonal injury and progressive neurodegeneration. The biological processes driving the disease are already active at clinical onset, yet comprehensive characterization of different molecular pathways at diagnosis remains limited. ObjectiveTo integrate high-sensitivity CSF biomarker profiling with clinical disability measures, MRI lesion burden, and microstructural diffusion metrics in normal-appearing white matter (NAWM) in treatmentnaïve new diagnosed Multiple Sclerosis patients.MethodsCSF samples were collected from 70 treatment-naïve newly diagnosed MS patients and 11 age- and sex-matched healthy controls. A CNS Disease Panel of 120 CSF biomarkers was quantified using ultra-sensitive NULISA technology. Differential expression analysis was performed using false discovery rate (FDR) correction. Multivariable linear regression models adjusted for age, sex, and ethnicity were used to evaluate associations with baseline Expanded Disability Status Scale (EDSS), short-term clinical change after high-dose corticosteroid therapy (ΔEDSS) and MRI white matter lesion volume. Partial correlation analyses were performed to assess associations between CSF and diffusion MRI measures in NAWM regions of interest.ResultsSeven biomarkers were significantly increased in MS compared with controls after FDR correction: REST, IL-16, CHI3L1, NEFL, ICAM-1, TREM2, and CHIT1. Correlation analysis demonstrated clustering among markers of glial and innate immune activation (CHI3L1, TREM2, CHIT1) and moderate associations between NFL and glial markers. REST was strongly correlated with IL16, suggesting early transcriptional and immune pathway interplay.In multivariable models, higher levels of glial activation markers were independently associated with greater baseline disability. CSF NFL levels correlated with white matter lesion burden and were significantly associated with diffusion abnormalities in NAWM, particularly in the genu of the corpus callosum, cingulum, and anterior corona radiata, indicating that neuroaxonal injury reflects both focal inflammatory activity and diffuse microstructural damage beyond visible lesions.DiscussionThis application of ultra-sensitive NULISA multiplex CSF profiling in treatment-naïve MS at diagnosis demonstrates that multiple immunological and neurodegenerative pathways are simultaneously active at disease onset and are associated with early disability and microstructural white matter damage. These findings support the concept that inflammatory and neurodegenerative processes occur in parallel early in MS and suggest that integrated CSF biomarker profiling may improve early disease characterization.ConclusionsMultiplex CSF proteomic profiling using NULISA identifies biologically meaningful biomarker signatures at MS disease onset. Integration of multiplex biomarkers with clinical and imaging measures may improve early disease stratification and support personalized therapeutic strategies.

  • Open Access

    Plasma p-tau isoform profiles identify biologically distinct severity strata in Alzheimer’s disease

    by Andrea Toja, Eqrem Rusi, Chiara Tolassi, Alice Galli, Chiara Trasciatti, Irene Girotto, Andrea L. Benedet, Virginia Quaresima, Diego Bertoli, Cristina Mordenti, et al.

    Background: Plasma phosphorylated tau (p-tau) isoforms are established biomarkers of Alzheimer’s disease (AD), but whether their combined elevation reflects biological heterogeneity within AD remains unclear.Objective: To determine whether distinct plasma p-tau217, p-tau181, and p-tau231 profiles identify clinically and biologically meaningful severity strata within biologically confirmed AD.Methods: We included 106 patients with CSF-confirmed AD at the mild cognitive impairment or dementia stage. Participants underwent clinical assessment, CSF Aβ42 and tau biomarker measurement, and plasma assessment of p-tau217, p-tau181, p-tau231, Aβ42/Aβ40, GFAP, and NfL. Longitudinal MMSE data were available in 80 participants over a mean 2.6-year follow-up. Patients were classified using ROC-derived multi-isoform profiles and, separately, p-tau217 quintiles. Clinical and biological group differences and age- and sex-adjusted regression models were evaluated.Results: Multi-isoform profiling identified five profiles, ranging from all-intermediate p-tau isoforms to triple-high. Compared with the all-intermediate profile, profiles with broader p-tau isoform elevation showed higher CSF tau markers, higher plasma GFAP and NfL, and faster annualized MMSE decline. The triple-high profile showed worst cognitive performance and highest plasma biomarker burden. Complementary p-tau217 quintile stratification showed a parallel severity gradient, with higher quintiles associated with increased CSF tau markers, GFAP, NfL, and cognitive decline. Regression analyses supported p-tau217 as the strongest single-marker correlate, whereas p-tau231 contributed to NfL and CSF t-tau models.Conclusions: Multi-isoform plasma p-tau profiling identifies biologically distinct AD severity strata, consistent with a hierarchy of increasing tau phosphorylation burden. p-tau217 captures much of this continuum and remains the most robust single-marker correlate, whereas p-tau231 may provide complementary information on neurodegeneration-related biology.

  • Open Access

    Matrix matters: head-to-head concordance of serum and plasma for NULISAseq CNS Disease Panel

    by Tommaso Merati, Chiara Tolassi, Alessandro Rondina, Irene Girotto, Marianna Bertoni, Eileen Mac Sweeney, Andrea Toja, Eqrem Rusi, Caterina Martinuzzo, Andrea Pilotto, et al.

    Blood-based proteomic profiling is now widely applied in neurodegenerative and neuroinflammatory disease, yet the choice between serum and plasma remains poorly characterised for high-multiplex platforms. Many legacy biobanks hold mainly serum, whereas most current NUcleic-acid-Linked Immuno-Sandwich Assay (NULISA) studies use plasma. We compared the 130-protein NULISAseq central nervous system (CNS) Disease Panel head-to-head in matched serum and plasma collected at the same draw from 62 participants (30 neurodegenerative, 19 demyelinating, 13 healthy controls). Agreement was measured with Spearman correlation (rho), Lin’s concordance correlation coefficient (CCC), the intraclass correlation coefficient (ICC) and the mean paired serum-to-plasma difference (dNPQ). Concordance was moderate to high: 123 of 130 proteins reached significance and 18 reached rho >= 0.90, with a median rho of 0.72 (range 0.10-0.988). Proteins fell into three tiers. Cytoskeletal markers (NEFH rho=0.988; NEFL rho=0.947) and glial GFAP (rho=0.949, |dNPQ|<0.5) were interchangeable between matrices. Phosphorylated tau (pTau) species retained excellent rank concordance but carried a systematic plasma-greater-than-serum offset (pTau-181 rho=0.869, dNPQ=+0.67; pTau-217 rho=0.846, dNPQ=+0.64; pTau-231 rho=0.885, dNPQ=+0.89). Platelet-derived analytes (CD40LG rho=0.102, dNPQ=-4.74; BDNF rho=0.223, dNPQ=-2.69) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) diverged markedly. For most clinically relevant neurodegeneration markers, especially cytoskeletal and glial proteins, serum is a valid substitute for plasma; absolute thresholds for phosphorylated tau and amyloid peptides require matrix-specific calibration, and platelet-sensitive analytes cannot be compared across matrices without strictly standardised pre-analytical conditions. Main Points: Across the 130-protein NULISAseq CNS Disease Panel, serum and plasma showed moderate-to-high overall concordance (median Spearman rho 0.72; 123/130 proteins significant). Neurofilaments (NEFH, NEFL) and GFAP were interchangeable between matrices, whereas phosphorylated tau species retained rank order but required matrix-specific calibration of absolute levels. Platelet-derived (CD40LG, BDNF) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) were not comparable across matrices without strict pre-analytical standardisation.